Description:
An agonist of TLR7 with immune response modifying activity, Approved for basal cell carcinoma, In Phase III for VIN and CIN, Imiquimod's proapoptotic activity appears to be related to Bcl-2 overexpression in susceptible tumor cells.
- Molecular Weight:240.30
- Boiling Point:456.7±48.0°C at 760 mmHg
- Melting Point:292-294°C
- Purity:>98%
Molecular Formula:
C14H16N4
Canonical SMILES:
CC(C)CN1C=NC2=C1C3=CC=CC=C3N=C2N
InChI:
InChI=1S/C14H16N4/c1-9(2)7-18-8-16-12-13(18)10-5-3-4-6-11(10)17-14(12)15/h3-6,8-9H,7H2,1-2H3,(H2,15,17)
InChIKey:
DOUYETYNHWVLEO-UHFFFAOYSA-N
Solubility:
Soluble in Aqueous Acid (Slightly), DMSO (Very Slightly, Heated)
Appearance:
Off-White Solid
Application:
An immune response modifier. It stimulates the production of interferon-a
Storage: Store at -20°C
Synonyms:
1-(2-Methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine; R-837; S-26308; Aldara; TMX-101; 1H-Imidazo[4,5-c]quinolin-4-amine, 1-(2-methylpropyl)-; 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-amine; 1-Isobutyl-1H-imidazo[4,5-c]quinolin-4-ylamine; Aldara; Beselna; Keravort; R 837; R837; S 26308; TMX 101; Zartra; Zyclara Más detalles se encuentran
aquí
details
details